Merck (MRK) Accounts Payables (2009 - 2026)
Merck (MRK) posted quarterly Accounts Payables of $3.9 billion for Q1 2026, up 2.09% year-over-year from $3.8 billion in Q1 2025, and down 12.28% quarter-over-quarter from $4.4 billion in Q4 2025.
Merck (MRK) Accounts Payables (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Accounts Payables for 18 consecutive years, with $3.9 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables rose 2.09% year-over-year to $3.9 billion; the TTM figure through Mar 2026 stood at $3.9 billion (up 2.09% YoY), while the FY2025 annual figure was $4.4 billion, up 7.97% from the prior year.
- Accounts Payables fell to $3.9 billion in Q1 2026 per MRK's latest filing, from $4.4 billion in the prior quarter.
- Across five years, Accounts Payables topped out at $4.4 billion in Q4 2025 and bottomed at $3.4 billion in Q3 2022.
- Historically, Accounts Payables has averaged $3.8 billion across 5 years, with a median of $3.7 billion in 2022.
- Annual changes were most pronounced in 2022 — Accounts Payables slipped 10.65% — and 2025, when it climbed 15.64%.
- Merck's Accounts Payables stood at $4.3 billion in 2022, then fell by 8.02% to $3.9 billion in 2023, then advanced by 4.0% to $4.1 billion in 2024, then grew by 7.97% to $4.4 billion in 2025, then retreated by 12.28% to $3.9 billion in 2026.
- Business Quant data shows MRK's Accounts Payables at $3.9 billion in Q1 2026, $4.4 billion in Q4 2025, and $4.1 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 9.22 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 33.30 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 3.83 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 4.26 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 22.89 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 2.87 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 674.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 4.58 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -19.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 8.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.83 Bn |
| Mar 31, 2026 | 3.86 Bn |
| Dec 31, 2025 | 4.40 Bn |
| Sep 30, 2025 | 4.15 Bn |
| Jun 30, 2025 | 3.89 Bn |
| Mar 31, 2025 | 3.78 Bn |
| Dec 31, 2024 | 4.08 Bn |
| Sep 30, 2024 | 3.59 Bn |
| Jun 30, 2024 | 3.52 Bn |
| Mar 31, 2024 | 3.51 Bn |
| Dec 31, 2023 | 3.92 Bn |
| Sep 30, 2023 | 3.51 Bn |
| Jun 30, 2023 | 3.44 Bn |
| Mar 31, 2023 | 3.68 Bn |
| Dec 31, 2022 | 4.26 Bn |
| Sep 30, 2022 | 3.37 Bn |
| Jun 30, 2022 | 3.48 Bn |
| Mar 31, 2022 | 3.72 Bn |
| Dec 31, 2021 | 4.61 Bn |
| Sep 30, 2021 | 3.37 Bn |